THJ-2201

Synthetic cannabinoid From Wikipedia, the free encyclopedia

THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1][2][3][4]

Legal status
Quick facts Legal status, Identifiers ...
THJ-2201
Legal status
Legal status
Identifiers
  • [1-(5-Fluoropentyl)-1H-indazol-3-yl](1-naphthyl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H21FN2O
Molar mass360.432 g·mol−1
3D model (JSmol)
  • c1ccc2c(c1)cccc2C(=O)c3c4ccccc4n(n3)CCCCCF
  • InChI=1S/C23H21FN2O/c24-15-6-1-7-16-26-21-14-5-4-12-20(21)22(25-26)23(27)19-13-8-10-17-9-2-3-11-18(17)19/h2-5,8-14H,1,6-7,15-16H2
  • Key:DULWRYKFTVFPTL-UHFFFAOYSA-N
Close

It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.[5]

Pharmacology

THJ-2201 acts as a full agonist with a binding affinity of 1.34 nM at CB1 and 1.32 nM at CB2 cannabinoid receptors.[6]

Side effects

THJ-2201 has been linked to at least one hospitalization and death due to its use.[7]

It is classified as a Schedule I controlled substance in the United States.[8]

It is also an Anlage II controlled drug in Germany.[9]

See also

References

Related Articles

Wikiwand AI